Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) shares saw strong trading volume on Monday . 376,600 shares traded hands during mid-day trading, an increase of 17% from the previous session’s volume of 322,491 shares.The stock last traded at €21.05 and had previously closed at €21.76.
Analyst Ratings Changes
A number of analysts have recently issued reports on the stock. Morgan Stanley initiated coverage on shares of Stevanato Group in a report on Monday, December 1st. They issued an “equal weight” rating and a $24.00 price objective on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Stevanato Group in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Stevanato Group has a consensus rating of “Moderate Buy”.
View Our Latest Stock Report on STVN
Stevanato Group Trading Up 0.6%
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. CIBC Bancorp USA Inc. acquired a new stake in shares of Stevanato Group during the third quarter worth $737,000. Quantessence Capital LLC bought a new position in Stevanato Group during the third quarter worth about $526,000. Mariner LLC raised its stake in Stevanato Group by 6.9% in the 3rd quarter. Mariner LLC now owns 25,447 shares of the company’s stock worth $655,000 after purchasing an additional 1,638 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Stevanato Group in the 3rd quarter worth about $4,155,000. Finally, Bamco Inc. NY boosted its holdings in Stevanato Group by 4.5% in the 3rd quarter. Bamco Inc. NY now owns 1,973,759 shares of the company’s stock valued at $50,824,000 after purchasing an additional 85,709 shares during the period.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Recommended Stories
- Five stocks we like better than Stevanato Group
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Financial Sector Breaks Out as Capital Rotates and Leadership Shifts
- 3 REITs to Buy and Hold for the Long Term
- Super Micro’s Sell-Off Is a Mirage—Here’s Why the Rally May Come Back Fast
- 10 Best Airline Stocks to Buy
- 3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
